MA55594A - Composés hexahydro-1h-pyrazino[1,2-a]pyrazine pour le traitement d'une maladie auto-immune - Google Patents
Composés hexahydro-1h-pyrazino[1,2-a]pyrazine pour le traitement d'une maladie auto-immuneInfo
- Publication number
- MA55594A MA55594A MA055594A MA55594A MA55594A MA 55594 A MA55594 A MA 55594A MA 055594 A MA055594 A MA 055594A MA 55594 A MA55594 A MA 55594A MA 55594 A MA55594 A MA 55594A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazino
- hexahydro
- treatment
- autoimmune disease
- pyrazine compounds
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- XPPVFPABNTZREL-UHFFFAOYSA-N C1C=2N(CCN1)CCNC=2 Chemical class C1C=2N(CCN1)CCNC=2 XPPVFPABNTZREL-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019081900 | 2019-04-09 | ||
| CN2019121598 | 2019-11-28 | ||
| CN2020078225 | 2020-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55594A true MA55594A (fr) | 2022-02-16 |
Family
ID=70228042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055594A MA55594A (fr) | 2019-04-09 | 2020-04-07 | Composés hexahydro-1h-pyrazino[1,2-a]pyrazine pour le traitement d'une maladie auto-immune |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220340597A1 (fr) |
| EP (1) | EP3953356B1 (fr) |
| JP (1) | JP7692838B2 (fr) |
| KR (1) | KR20210149163A (fr) |
| CN (1) | CN113710672B (fr) |
| AU (1) | AU2020272467A1 (fr) |
| BR (1) | BR112021020297A2 (fr) |
| CA (1) | CA3135129A1 (fr) |
| CL (1) | CL2021002621A1 (fr) |
| CO (1) | CO2021013166A2 (fr) |
| CR (1) | CR20210513A (fr) |
| IL (1) | IL286870A (fr) |
| MA (1) | MA55594A (fr) |
| MX (1) | MX2021012223A (fr) |
| PE (1) | PE20212178A1 (fr) |
| PH (1) | PH12021552533A1 (fr) |
| SG (1) | SG11202110401WA (fr) |
| TW (1) | TW202104230A (fr) |
| WO (1) | WO2020207991A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114599652B (zh) * | 2019-10-31 | 2024-07-12 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物 |
| WO2021094301A1 (fr) * | 2019-11-12 | 2021-05-20 | F. Hoffmann-La Roche Ag | Composés d'hydropyrazino[1,2-b]isoquinoline pour le traitement d'une maladie auto-immune |
| EP4061816A1 (fr) | 2019-11-19 | 2022-09-28 | F. Hoffmann-La Roche AG | Composés d'hydro-1 h-pyrrolo[1,2-a]pyrazine pour le traitement d'une maladie auto-immune |
| US12503471B2 (en) | 2019-11-19 | 2025-12-23 | Hoffmann-La Roche Inc. | Triazatricycle compounds for the treatment of autoimmune disease |
| US12478621B2 (en) | 2019-11-28 | 2025-11-25 | Deutsches Krebsforschungszentrum | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| CN114761406B (zh) | 2019-12-03 | 2024-04-19 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物 |
| JP2023533807A (ja) * | 2020-07-14 | 2023-08-04 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2663555T3 (en) * | 2011-01-12 | 2017-03-27 | Ventirx Pharmaceuticals Inc | SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS |
| HRP20171981T1 (hr) | 2012-09-14 | 2018-02-09 | F. Hoffmann - La Roche Ag | Derivati pirazolkarboksamida kao taar modulatora za uporabu u liječenju nekoliko poremećaja poput depresije, dijabetesa i parkinsonove bolesti |
| US9643967B2 (en) * | 2013-12-13 | 2017-05-09 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors |
| MX2021006804A (es) | 2015-12-17 | 2023-01-13 | Merck Patent Gmbh | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. |
| JP2021527100A (ja) * | 2018-06-13 | 2021-10-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 自己免疫疾患の処置のためのピリジニルヘテロシクリル化合物 |
| CN112752755A (zh) * | 2018-09-27 | 2021-05-04 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的杂环基化合物 |
-
2020
- 2020-04-07 US US17/602,057 patent/US20220340597A1/en not_active Abandoned
- 2020-04-07 PH PH1/2021/552533A patent/PH12021552533A1/en unknown
- 2020-04-07 CR CR20210513A patent/CR20210513A/es unknown
- 2020-04-07 EP EP20717841.9A patent/EP3953356B1/fr active Active
- 2020-04-07 AU AU2020272467A patent/AU2020272467A1/en not_active Abandoned
- 2020-04-07 WO PCT/EP2020/059831 patent/WO2020207991A1/fr not_active Ceased
- 2020-04-07 BR BR112021020297A patent/BR112021020297A2/pt not_active Application Discontinuation
- 2020-04-07 KR KR1020217036391A patent/KR20210149163A/ko not_active Withdrawn
- 2020-04-07 SG SG11202110401WA patent/SG11202110401WA/en unknown
- 2020-04-07 PE PE2021001647A patent/PE20212178A1/es unknown
- 2020-04-07 MA MA055594A patent/MA55594A/fr unknown
- 2020-04-07 JP JP2021559754A patent/JP7692838B2/ja active Active
- 2020-04-07 MX MX2021012223A patent/MX2021012223A/es unknown
- 2020-04-07 CN CN202080030189.2A patent/CN113710672B/zh active Active
- 2020-04-07 CA CA3135129A patent/CA3135129A1/fr active Pending
- 2020-04-08 TW TW109111749A patent/TW202104230A/zh unknown
-
2021
- 2021-09-30 IL IL286870A patent/IL286870A/en unknown
- 2021-09-30 CO CONC2021/0013166A patent/CO2021013166A2/es unknown
- 2021-10-06 CL CL2021002621A patent/CL2021002621A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020272467A1 (en) | 2021-10-14 |
| WO2020207991A1 (fr) | 2020-10-15 |
| PH12021552533A1 (en) | 2022-06-20 |
| PE20212178A1 (es) | 2021-11-09 |
| EP3953356C0 (fr) | 2023-07-26 |
| EP3953356B1 (fr) | 2023-07-26 |
| CO2021013166A2 (es) | 2021-12-10 |
| SG11202110401WA (en) | 2021-10-28 |
| BR112021020297A2 (pt) | 2021-12-14 |
| CN113710672A (zh) | 2021-11-26 |
| IL286870A (en) | 2021-10-31 |
| EP3953356A1 (fr) | 2022-02-16 |
| JP7692838B2 (ja) | 2025-06-16 |
| CN113710672B (zh) | 2025-01-03 |
| CR20210513A (es) | 2021-11-02 |
| MX2021012223A (es) | 2021-11-03 |
| CA3135129A1 (fr) | 2020-10-15 |
| TW202104230A (zh) | 2021-02-01 |
| KR20210149163A (ko) | 2021-12-08 |
| JP2022527588A (ja) | 2022-06-02 |
| CL2021002621A1 (es) | 2022-05-13 |
| US20220340597A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3953356C0 (fr) | Composés hexahydro-1h-pyrazino[1,2-a]pyrazine pour le traitement d'une maladie auto-immune | |
| MA52747A (fr) | Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune | |
| EP3820537A4 (fr) | Vecteurs de thérapie génique pour le traitement de la maladie de danon | |
| EP3675859A4 (fr) | Composés, compositions et méthodes pour le traitement d'une maladie | |
| EP3880823A4 (fr) | Virus adéno-associé thérapeutique pour le traitement de la maladie de pompe | |
| MA53661A (fr) | Agonistes du récepteur farnésoïde x pour le traitement d'une maladie | |
| EP4034530A4 (fr) | Inhibiteurs de la protéine kinase i interagissant avec des récepteurs pour le traitement d'une maladie | |
| EP3790867A4 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
| EP3924371A4 (fr) | Vecteurs de thérapie génique pour le traitement de la maladie de danon | |
| EP3737361A4 (fr) | Inhibiteurs de la dihydrocéramide désaturase pour le traitement d'une maladie | |
| MA55199A (fr) | Leucine, acétyl leucine et analogues apparentés pour le traitement d'une maladie | |
| MA54544A (fr) | Inhibiteurs de la voie jak1 pour le traitement d'une maladie gastro-intestinale | |
| EP3986863A4 (fr) | Inhibiteurs de glycolate oxydase pour le traitement d'une maladie | |
| MA49906A (fr) | Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie | |
| MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
| EP4065565A4 (fr) | Inhibiteurs de la protéine kinase 1 interagissant avec les récepteurs pour le traitement d'une maladie | |
| EP4110765A4 (fr) | Inhibiteurs de la protéine kinase i interagissant avec le récepteur pour le traitement d'une maladie | |
| EP4743465A1 (fr) | Macrocycles bicycliques pour le traitement d'une maladie auto-immune | |
| EP3504204A4 (fr) | Indazolyl-l,2,4-thiadiazolamines et composés apparentés pour l'inhibition de protéine kinase associée à rho et le traitement de la maladie | |
| EP3911329A4 (fr) | Composition pour la prévention ou le traitement d'une maladie du foie métabolique | |
| EP4121048A4 (fr) | Agonistes du récepteur de farnésoïde x pour le traitement d'une maladie | |
| EP4069700A4 (fr) | Macrocycles destinés à être utilisés dans le traitement d'une maladie | |
| EP3781695A4 (fr) | Importation d'arn mitochondrial pour le traitement d'une maladie mitochondriale | |
| EP4054606A4 (fr) | Utilisation des vésicules liées à la matrice pour le traitement d'une maladie auto-immune | |
| EP4298094A4 (fr) | Analogues pour le traitement d'une maladie |